HS
HighVista Strategies Portfolio holdings
AUM
$272M
1-Year Return
24.34%
This Quarter Return
+12.21%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$290M
AUM Growth
+$16.2M
(+5.9%)
Cap. Flow
-$2.16M
Cap. Flow
% of AUM
-0.74%
Top 10 Holdings %
Top 10 Hldgs %
25.51%
Holding
174
New
37
Increased
46
Reduced
48
Closed
32
Top Buys
| 1 |
GE Vernova
GEV
|
$3.75M |
| 2 |
Amgen
AMGN
|
$3.25M |
| 3 |
Protagonist Therapeutics
PTGX
|
$3.07M |
| 4 |
Amazon
AMZN
|
$2.65M |
| 5 |
Edgewise Therapeutics
EWTX
|
$2.37M |
Top Sells
| 1 |
Insmed
INSM
|
$5.94M |
| 2 |
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
|
$4.02M |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$3.97M |
| 4 |
Merus
MRUS
|
$2.14M |
| 5 |
Meta Platforms (Facebook)
META
|
$2.06M |
Sector Composition
| 1 | Healthcare | 46.45% |
| 2 | Technology | 15.69% |
| 3 | Consumer Discretionary | 9.1% |
| 4 | Industrials | 4.98% |
| 5 | Financials | 4.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Cytokinetics
CYTK
$5.95B
| $531K | 0.18% |
+10,055
| New | +$531K |
|
127
Mirum Pharmaceuticals
MIRM
$3.73B
| $529K | 0.18% |
13,571
-6,637
| -33% | -$259K |
|
128
AnaptysBio
ANAB
$590M
| $522K | 0.18% |
+15,574
| New | +$522K |
|
129
Immatics
IMTX
$695M
| $520K | 0.18% |
45,544
-32,277
| -41% | -$368K |
|
130
89bio
ETNB
$1.28B
| $494K | 0.17% |
+66,787
| New | +$494K |
|
131
UroGen Pharma
URGN
$870M
| $490K | 0.17% |
+38,566
| New | +$490K |
|
132
Disc Medicine
IRON
$2.09B
| $470K | 0.16% |
+9,565
| New | +$470K |
|
133
Madrigal Pharmaceuticals
MDGL
$9.61B
| $469K | 0.16% |
2,211
-323
| -13% | -$68.5K |
|
|
TSVT
134
DELISTED
2seventy bio
TSVT
| $451K | 0.16% |
95,454
+1,954
| +2% | +$9.22K |
|
135
Natera
NTRA
$22.9B
| $437K | 0.15% |
3,440
-128
| -4% | -$16.3K |
|
136
Alnylam Pharmaceuticals
ALNY
$59.4B
| $427K | 0.15% |
1,551
-1,051
| -40% | -$289K |
|
137
Pharvaris
PHVS
$1.41B
| $422K | 0.15% |
22,768
+6,018
| +36% | +$111K |
|
138
Kura Oncology
KURA
$706M
| $413K | 0.14% |
21,161
+4,397
| +26% | +$85.9K |
|
139
Acadia Pharmaceuticals
ACAD
$4.3B
| $389K | 0.13% |
25,287
-591
| -2% | -$9.09K |
|
140
KalVista Pharmaceuticals
KALV
$765M
| $386K | 0.13% |
33,305
+1,432
| +4% | +$16.6K |
|
141
Tyra Biosciences
TYRA
$647M
| $378K | 0.13% |
16,078
| – | – |
|
142
Celldex Therapeutics
CLDX
$1.51B
| $305K | 0.11% |
8,981
-646
| -7% | -$22K |
|
143
Equity Residential
EQR
$25B
| – | – |
-25,900
| Closed | -$1.8M |
|
144
4D Molecular Therapeutics
FDMT
$309M
| – | – |
-15,532
| Closed | -$326K |
|
145
FirstService
FSV
$9.21B
| – | – |
-8,700
| Closed | -$1.33M |
|
146
Huazhu Hotels Group
HTHT
$11.2B
| – | – |
-19,029
| Closed | -$634K |
|
147
HubSpot
HUBS
$24.5B
| – | – |
-2,100
| Closed | -$1.24M |
|
148
IDEAYA Biosciences
IDYA
$2.26B
| – | – |
-40,856
| Closed | -$1.43M |
|
149
JB Hunt Transport Services
JBHT
$14.1B
| – | – |
-8,000
| Closed | -$1.28M |
|
|
150
Meta Platforms (Facebook)
META
$1.88T
| – | – |
-4,090
| Closed | -$2.06M |
|